Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.67 - $41.87
Previous CloseN/A
Volume45.37K
Average Volume (3M)86.92K
Market Cap
$376.69M
Enterprise Value$141.57M
Total Cash (Recent Filing)$212.61M
Total Debt (Recent Filing)$13.98M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
May 07, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-52.64
Shares Outstanding25,907,100
10 Day Avg. Volume106,034
30 Day Avg. Volume86,925
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.69
Price to Cash Flow (P/CF)-14.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda-1.86
Forecast
1Y Price Target
$37.33Price Target Upside156.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Cartesian Therapeutics News
See All RNAC News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe likelihood of success for the Phase III AURORA trial is very high given the impressive Phase IIb data.
Financial HealthCartesian's balance sheet should support operations into mid-2027, including the completion of the planned Phase 3 AURORA trial of Descartes-08 in myasthenia gravis.
Regulatory DevelopmentsCartesian received a Special Protocol Assessment (SPA) agreement on the study design for the Descartes-08's Phase 3 AURORA study in MG, which helps de-risk the Phase 3 trial.
Bears Say
Market PerceptionThe AURORA Phase 3 trial is the only registrational study Cartesian needs to support a BLA submission based on the recent SPA agreement with the FDA, which is an underappreciated regulatory de-risking event.
Stock Price TargetDespite positive developments, the price target for Cartesian Therapeutics has been adjusted from $45 to $40.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $11.66 and its highest was $41.87 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $376.69M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 37 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.591 earnings per share for the quarter, beating the consensus estimate of -$0.83 by $0.239.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 25,907,100 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$0.591 in its last earnings report, beating expectations of -$0.83. Following the earnings report the stock price went down -4.977%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
---
Cartesian Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.33 (156.74% Upside)
$37.33 (156.74% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 100.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.43%
12-Months-Change
Fundamentals
Return on Equity
-938.38%
Trailing 12-Months
Asset Growth
329.41%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
---
RNAC Stock 12 Month Forecast
Average Price Target
$37.33
▲(156.74% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
ImmunityBio
―
Crispr Therapeutics AG
―
Cabaletta Bio
―
Best Analysts Covering RNAC
1 Year
1 Year Success Rate
10/30 ratings generated profit
1 Year Average Return
-17.78%
reiterated a buy rating 8 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -17.78% per trade.
---